IceCure Medical Ltd. (NASDAQ: ICCM) developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent titled "Cryoprobe".
This invention introduces a novel method for safely and efficiently extracting the cryoprobe after tissue freezing during cryoablation procedures. The cryoprobe's tip is integrated with a heater, temperature sensor, and controlled gas pulses, enabling precise estimation and management of the cryoprobe's external surface temperature—even while embedded in frozen tissue. Designed to be compatible with a wide range of XSense™ system cryoprobe types, the new cryoprobe technology is a versatile solution for multiple clinical scenarios.
IceCure's platform technology, including the ProSense® Cryoablation System and XSense™ Cryoablation System and CryoProbes, provides a minimally invasive treatment option to destroy tumors by freezing them. The systems uniquely harness the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ICCM shares failed to advance from Wednesday’s $1.02.
